PCM
NVET

Prelude Capital Management’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Prelude Capital Management’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-22,876
Closed -$153K – 2106
2017
Q2 		$153K Buy
+22,876
New +$144K 0.01% 660

Prelude Capital Management's NVET Position: Q3 2017 in Review

Prelude Capital Management sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2017, closing a stake of 22,876 shares — an estimated $153K sold.

Prelude Capital Management first reported a position in NVET in Q2 2017 and held it in 1 quarter. The position peaked at $153K in Q2 2017. 0 funds tracked by Wall St. Rank hold NVET as of Q3 2017.

  • Prelude Capital Management reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Prelude Capital Management sold 22,876 Nexvet Biopharma plc Ordinary Shares shares in Q3 2017, an estimated $153K.
  • Prelude Capital Management first reported a position in Nexvet Biopharma plc Ordinary Shares in Q2 2017 and held it in 1 quarter.
  • Prelude Capital Management's Nexvet Biopharma plc Ordinary Shares position peaked at $153K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2017.

Based on Prelude Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.